<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9300">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02985866</url>
  </required_header>
  <id_info>
    <org_study_id>iDCL</org_study_id>
    <secondary_id>UC4DK108483</secondary_id>
    <nct_id>NCT02985866</nct_id>
  </id_info>
  <brief_title>The International Diabetes Closed Loop (iDCL) Trial: Main Protocol</brief_title>
  <acronym>iDCL Main</acronym>
  <official_title>Clinical Acceptance of the Artificial Pancreas: the International Diabetes Closed Loop (iDCL) Trial: A Randomized Clinical Trial to Assess the Efficacy of Adjunctive Closed Loop Control Versus Sensor-Augmented Pump Therapy in the Management of Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stacey Anderson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TypeZero Technologies, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tandem Diabetes Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>DexCom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ascensia Diabetes Care</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the efficacy and safety of home use of a
      Control-to-Range (CTR) closed-loop (CL) system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The protocol is a 6-month parallel group multi-center randomized trial designed to compare
      Control-to-Range (CTR) closed-loop (CL) with sensor augmented pump therapy (SAP).
      Approximately 240 subjects will be entered into the randomized trial at approximately ten
      clinical sites in the United States and Europe, such that at least 207 subjects complete the
      randomized trial. The goal will be to randomize approximately 115 subjects with HbA1c ≥7.5%
      and 125 subjects with HbA1c &lt; 7.5%, with the minimum being 92 subjects with HbA1c &lt;7.5% and
      86 with HbA1c &gt;7.5%.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The co-primary outcomes are differences in CGM-measured metrics between baseline and 6-month post-336 randomization period: - superiority in CGM-measured time below 70 mg/dL, and 338 - non-inferiority in CGM-measured time above 180 mg/dL</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Among subjects with HbA1c ≥7.5%, difference in HbA1c improvement between SAP and CTR at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Among subjects with HbA1c &lt;7.5%, difference in CGM-measured time below 70 mg/dL between baseline and 6-month post-randomization period</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Type1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Artificial Pancreas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be provided the Artificial Pancreas (AP) system which includes the inControl Diabetes Management Platform, a study insulin pump, study continuous glucose monitor (CGM), and a study glucometer. This AP system is designed to help control blood sugar in people living with type 1 diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sensor Augmented Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will continue to use their personal insulin pump with a study continuous glucose monitor (CGM) and study glucometer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Artificial Pancreas</intervention_name>
    <description>Use of CTR at home for 6 months</description>
    <arm_group_label>Artificial Pancreas</arm_group_label>
    <other_name>Control-to-Range (CTR) closed-loop (CL)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sensor Augmented Therapy</intervention_name>
    <description>Use of personal pump with study CGM &amp; glucometer at home for 6 months</description>
    <arm_group_label>Sensor Augmented Therapy</arm_group_label>
    <other_name>SAP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>continuous glucose monitor (CGM)</intervention_name>
    <arm_group_label>Sensor Augmented Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least
             one year and using insulin for at least 1 year

          2. Use of an insulin pump for at least 6 months

          3. Age ≥14 years old

          4. HbA1c level &lt;10.5% at screening

          5. For females, not currently known to be pregnant

          6. Willingness not to add glucose-lowering agents (such as Pramlintide, Metformin, GLP-1
             analogs, SGLT2 inhibitors) during the study

          7. Willingness, if using the closed-loop system, to stop closed-loop when taking
             acetaminophen and avoid closed-loop for at least 4 hours afterward

          8. Willingness to suspend use of any personal CGM for the duration of the clinical trial
             once the unblinded study CGM is in use

          9. Willingness to establish network connectivity on at least a weekly basis either via
             local Wifi network or via a study-provided cellular service

         10. Currently using no insulins other than one of the following rapid-acting insulins at
             the time of enrollment: insulin lispro (Humalog), insulin aspart (Novolog), or
             insulin glulisine (Apidra)

         11. Investigator has confidence that the subject can successfully operate all study
             devices and is capable of adhering to the protocol

        Exclusion Criteria:

          1. More than one episode of diabetic ketoacidosis (DKA) in the 6 months prior to
             enrollment

          2. More than one episode of severe hypoglycemia involving seizure or loss of
             consciousness in the 6 months prior to enrollment

          3. Medical need for chronic acetaminophen

          4. Use of any glucose-lowering agent (such as Pramlintide, Metformin, GLP-1 analogs,
             SGLT2 inhibitors) in the 3 months prior to enrollment

          5. Hemophilia or any other bleeding disorder

          6. A condition, which in the opinion of the investigator or designee, would put the
             participant or study at risk

          7. Participation in another pharmaceutical or device trial at the time of enrollment or
             during the study

          8. Use of a closed-loop system within the last month prior to enrollment

          9. Employed by, or having immediate family members employed by TypeZero Technologies,
             LLC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris P. Kovatchev, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia Center for Diabetes Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stacey M. Anderson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Virginia Center for Diabetes Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stacey M. Anderson, MD</last_name>
    <phone>434-982-0945</phone>
    <email>sg4c@virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emma Emory, RN</last_name>
    <phone>434-243-3992</phone>
    <email>ee9m@virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>William Sansum Diabetes Center</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jordan Pinsker, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Mei Mei Church, NP</last_name>
      <phone>805-682-7640</phone>
      <phone_ext>265</phone_ext>
      <email>mchurch@sansum.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jordan Pinsker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mei Mei Church, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruce Buckingham, MD</last_name>
      <phone>650-723-5791</phone>
      <email>bbendo@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eliana Frank</last_name>
      <phone>650-736-6642</phone>
      <email>elianaf@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bruce Buckingham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center, University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>R. Paul Wadwa, MD</last_name>
      <phone>303-724-2323</phone>
      <email>paul.wadwa@ucdenver.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emily Jost, MPH RD CDE</last_name>
      <phone>(303) 724-7313</phone>
      <email>emily.jost@ucdenver.edu</email>
    </contact_backup>
    <investigator>
      <last_name>R. Paul Wadwa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harvard University (Joslin Diabetes Center)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lori Laffel, MD, MPH</last_name>
      <phone>617-732-2603</phone>
      <email>lori.laffel@joslin.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Louise Ambler-Osborn, CPNP</last_name>
      <phone>617-732-2603</phone>
      <email>louise.ambler-osborn@joslin.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Francis Doyle, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lori Laffel, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shelly McCrady-Spitzer</last_name>
      <phone>507-255-5916</phone>
      <email>McCradySpitzer.Shelly@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Yogish C. Kudva, MBBS, MD</last_name>
      <email>kudva.yogish@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Yogish Kudva, MBBS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ananda Basu, MD, FRCP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carol Levy, MD, CDE</last_name>
      <phone>212-241-9089</phone>
      <email>selassie.ogyaadu@mssm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Camilla Levister, ANP-C, MS</last_name>
      <phone>212-241-5177</phone>
      <email>Camilla.Levister@mssm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Carol Levy, MD, CDE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Lam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Center for Diabetes Technology</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stacey M. Anderson, MD</last_name>
      <phone>434-982-0945</phone>
      <email>sg4c@virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emma Emory, RN</last_name>
      <phone>434-243-3992</phone>
      <email>ee9m@virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sue A. Brown, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda Gonder-Fredrick, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 16, 2017</lastchanged_date>
  <firstreceived_date>December 5, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Stacey Anderson</investigator_full_name>
    <investigator_title>CDT Medical Director</investigator_title>
  </responsible_party>
  <keyword>Artificial Pancreas</keyword>
  <keyword>Closed Loop Control</keyword>
  <keyword>Continuous Glucose Monitor (CGM)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>NIH's Data Sharing Policy on sharing research resources for research purposes to the scientific community will be followed. Data will be stored in a Data Archive Database includes CGM-insulin delivery time series, meal content, boluses, &amp; exercise will be deidentified &amp; retrievable only by subject ID number. The data's real value lies in their precise time stamps - each reading is coded by date &amp; time which makes possible the data to be related to the subjects' daily routine. Individual patterns of demographic &amp; insulin treatment parameters leave open a remote possibility of deductive disclosure of subjects with unusual characteristics. Data can be made available only under a Data-Sharing Agreement that includes: (1) a commitment to using the data only for research purposes &amp; not to identify participants; (2) a commitment to securing the data using appropriate computer technology; &amp; (3) a commitment to destroying or returning the data after analyses are completed.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
